Acute lymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:02:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute lymphocytic leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia https://clinicaltrials.eu/trial/long-term-safety-study-of-s68587-in-patients-with-advanced-lymphoid-leukemia-previously-treated-with-the-therapy/ Wed, 17 Jun 2026 04:03:10 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-s68587-in-patients-with-advanced-lymphoid-leukemia-previously-treated-with-the-therapy/ The study follows patients with Advanced lymphoid leukemia who have previously received an infusion of the experimental cell therapy called UCART19. This therapy consists of donor‑derived T cells that have been engineered to carry a CAR that recognizes the protein CD19 on the surface of the cancer cells. The cells are also modified by removing the genes TRAC and CD52 to reduce the risk of the immune system attacking the infused cells.

The purpose of the study is to evaluate the long‑term safety of the therapy. After the original infusion, participants will attend regular clinic visits over several years during which doctors will check for any health problems, record any side effects, and collect blood samples. Children will have additional assessments to see whether growth or puberty are affected.

During follow‑up, routine tests may include blood work, imaging scans if needed for clinical care, and, when part of standard care, a bone‑marrow sample to look for the engineered cells. All information gathered will be used only to understand how the therapy behaves over time and to identify any late‑appearing safety issues.

]]> Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-il-7r-jak-stat-pathway-mutations/ Thu, 07 May 2026 05:46:07 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-il-7r-jak-stat-pathway-mutations/ This clinical trial is focused on studying treatments for children with certain types of blood cancers, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, which have either returned after treatment or have not responded to previous treatments. The study involves two medications: Venetoclax, also known by its code name ABT-199, and Ruxolitinib, which is sometimes referred to as INCB018424. These medications are being tested for their effectiveness in treating these cancers, particularly in cases where there are specific genetic changes in the IL-7R/JAK-STAT signaling pathway, which is a part of the body’s cell communication system that can affect cancer growth.

The purpose of the study is to evaluate the safety and effectiveness of these medications in children. Participants in the study will receive either Venetoclax or Ruxolitinib, or a combination of both, in the form of oral tablets or suspensions. The study will be conducted in two phases. The first phase will focus on determining the safest dose of the medications, while the second phase will assess how well the medications work in treating the cancers. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on the potential benefits of Venetoclax and Ruxolitinib for children with these challenging types of blood cancers. The study is expected to continue until 2031, with recruitment starting in 2024.

]]> A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ Thu, 30 Apr 2026 13:08:36 +0000 https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ This study involves children with B-Cell Precursor Acute Lymphoblastic Leukemia, which is a type of blood cancer that affects white blood cells. The study focuses on two specific situations: when the disease has come back after treatment or has not responded to previous treatments (called relapsed or refractory), and when small amounts of cancer cells remain in the body even after treatment (called minimal residual disease positive). The treatment being tested is blinatumomab, which is given as an injection under the skin. This medication works by helping the body’s immune system find and attack cancer cells.

The purpose of the study is to test how safe and effective this under-the-skin method of giving blinatumomab is in children under 12 years of age, and to see if it can help eliminate cancer cells from the body. The study is divided into different parts. In the first part, doctors will check if the treatment is safe and well-tolerated in young children. In the second part, doctors will measure how well the treatment works by checking if cancer cells disappear from the bone marrow, which is the spongy tissue inside bones where blood cells are made.

During the study, children will receive the medication in treatment cycles, and doctors will regularly check their blood and bone marrow to see how the disease is responding. The study will also measure the levels of medication in the blood to understand how the body processes it, and will check if the body develops any reaction to the medication. Doctors will monitor for any side effects throughout the treatment period and will track how long any positive response to the treatment lasts.

]]> Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-blinatumomab-and-a-drug-combination-for-older-adults-with-newly-diagnosed-philadelphia-negative-b-cell-precursor-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:09:46 +0000 https://clinicaltrials.eu/trial/study-of-blinatumomab-and-a-drug-combination-for-older-adults-with-newly-diagnosed-philadelphia-negative-b-cell-precursor-acute-lymphoblastic-leukemia/ This study focuses on older adults with a newly diagnosed type of cancer called B-cell precursor Acute Lymphoblastic Leukemia. Specifically, the study looks at patients who are Philadelphia-negative, which means their cancer cells do not have a specific genetic marker. The purpose of the study is to compare a new treatment approach to the current standard of care to see how well it works and how safe it is.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.

]]> A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-subcutaneous-blinatumomab-in-adults-and-adolescents-with-relapsed-refractory-or-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblast/ Wed, 29 Apr 2026 15:09:46 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-subcutaneous-blinatumomab-in-adults-and-adolescents-with-relapsed-refractory-or-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblast/ This study focuses on B cell Precursor Acute Lymphoblastic Leukemia, a type of cancer that affects the blood and bone marrow. The research specifically involves individuals with Relapsed or Refractory B-ALL, which means the cancer has returned after previous treatment or has not responded to existing therapies. It also includes those with Minimal Residual Disease Positive (MRD+) B-ALL, a condition where very small amounts of cancer cells remain in the body even after treatment. The purpose of the study is to evaluate the safety and effectiveness of a new way to give the drug blinatumomab through a subcutaneous injection, which means the medicine is injected just under the skin rather than into a vein.

The study compares two different versions of the medication, referred to as SC1 and SC2. Other medications used as background treatments may include cytarabine, cyclophosphamide, dexamethasone, methotrexate, vincristine sulfate, and levetiracetam. Researchers will monitor how the body processes the medication, a process known as pharmacokinetics, and check for any side effects. The study is conducted in stages, starting with finding the right dose and then observing how well the treatment works in different groups of patients.

]]> Study of TranspoCART19 cell therapy for patients with CD19-positive acute lymphoblastic leukemia that is resistant or refractory to treatment https://clinicaltrials.eu/trial/study-of-transpocart19-cell-therapy-for-patients-with-cd19-positive-acute-lymphoblastic-leukemia-that-is-resistant-or-refractory-to-treatment/ Wed, 29 Apr 2026 15:08:35 +0000 https://clinicaltrials.eu/trial/study-of-transpocart19-cell-therapy-for-patients-with-cd19-positive-acute-lymphoblastic-leukemia-that-is-resistant-or-refractory-to-treatment/ This study is looking at a treatment for patients with CD19+ acute lymphoblastic leukemia that has not responded to previous treatments or has come back after treatment. The treatment being tested is called TranspoCART19, which is made from the patient’s own blood cells. These cells are collected from the patient’s blood and then changed in a laboratory to help them recognize and attack the leukemia cells. The modified cells are designed to find and destroy cells in the body that have a specific marker called CD19 on their surface, which is found on the leukemia cells.

The purpose of this study is to find out the safest dose of TranspoCART19 cells that can be given to patients and to see how well this treatment works in fighting the leukemia. The study is divided into two phases. In the first phase, different doses of the treatment will be tested to determine which dose is safe and can be tolerated by patients. In the second phase, the chosen dose will be used to see how effective it is at treating the leukemia.

During the study, patients will first have some of their blood cells collected through a process where blood is taken from the body, certain cells are separated out, and the remaining blood is returned to the body. These collected cells will then be modified in the laboratory and grown to create the TranspoCART19 treatment. After the treatment is prepared, it will be given back to the patient through an infusion, which means it will be slowly put into the bloodstream through a vein. Patients will be closely watched for any side effects and to see how well the treatment is working against the leukemia. Follow-up visits will continue for up to one year after receiving the treatment to monitor the patient’s condition and response to the therapy.

]]> A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ Wed, 29 Apr 2026 15:08:31 +0000 https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ This study is looking at two types of cancer that affect certain white blood cells. The first is B-cell precursor ALL, which is a cancer where the bone marrow makes too many immature white blood cells. The second is B-cell Non Hodgkin Lymphoma, which is a cancer that starts in white blood cells called lymphocytes and can affect lymph nodes and other parts of the body. Both of these cancers have either come back after previous treatment or have not responded to treatment. The study will use a treatment called MB-huCART19.1, which is a type of therapy where a patient’s own immune cells are collected and modified in a laboratory to better recognize and attack cancer cells that have a specific marker called CD19 on their surface. These modified cells, known as CAR T-cells, are then given back to the patient through intravenous infusion, which means the cells are delivered directly into a vein.

The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

]]> Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia https://clinicaltrials.eu/trial/study-of-olverembatinib-with-chemotherapy-versus-standard-therapy-in-adults-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:07:22 +0000 https://clinicaltrials.eu/trial/study-of-olverembatinib-with-chemotherapy-versus-standard-therapy-in-adults-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is studying a treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in newly diagnosed patients. The study tests a new medication called olverembatinib used together with chemotherapy drugs. The chemotherapy medications include vincristine, cytarabine, methotrexate, dexamethasone, and prednisolone.

The study compares two treatment approaches: one group receives olverembatinib with chemotherapy, while the other group receives different medications called tyrosine kinase inhibitors (which may include dasatinib, ponatinib, or imatinib) combined with the same chemotherapy drugs. The main purpose is to find out how well olverembatinib works compared to current treatments in eliminating cancer cells from the body.

During the study, patients will receive their assigned medications for several months. Doctors will regularly check the amount of cancer cells in the blood and bone marrow to see how well the treatment is working. They will also monitor patients for any side effects from the medications and track their overall health and survival over time.

]]> Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma https://clinicaltrials.eu/trial/study-of-tdt-3-cell-therapy-safety-in-patients-aged-1-year-and-older-with-relapsed-or-refractory-acute-leukemia-or-lymphoblastic-lymphoma/ Wed, 29 Apr 2026 15:06:57 +0000 https://clinicaltrials.eu/trial/study-of-tdt-3-cell-therapy-safety-in-patients-aged-1-year-and-older-with-relapsed-or-refractory-acute-leukemia-or-lymphoblastic-lymphoma/ This clinical trial studies the use of TdT-3, a special type of cell therapy that uses a patient’s own modified immune cells, in treating acute lymphoblastic leukemia or lymphoblastic lymphoma. These are serious blood cancers that have not responded to standard treatments or have returned after previous treatment. The therapy involves taking the patient’s own T-cells (a type of immune cell), modifying them in a laboratory to better recognize and fight cancer cells, and then returning them to the patient through an infusion into the bloodstream.

The purpose of this study is to test the safety of TdT-3 treatment and determine the most appropriate dose to use in future studies. Before receiving the cell therapy, patients will be given two medications called Fludarabine and Cyclophosphamide to prepare their body for the treatment. The treatment involves collecting the patient’s blood cells through a procedure called leukapheresis, processing these cells in a laboratory to create the TdT-3 therapy, and then giving the modified cells back to the patient.

During the study, doctors will closely monitor patients for any side effects and check how well the treatment works. They will take blood samples and perform various tests to track the modified cells in the body and measure the patient’s response to the treatment. The study will also look at how long the beneficial effects of the treatment last and whether patients can proceed to other treatments like stem cell transplantation if needed.

]]> Study on MB-CART2219.1 for Adults and Children with Relapsed or Refractory B-cell Malignancies https://clinicaltrials.eu/trial/study-on-mb-cart2219-1-for-adults-and-children-with-relapsed-or-refractory-b-cell-malignancies/ Wed, 29 Apr 2026 15:04:20 +0000 https://clinicaltrials.eu/trial/study-on-mb-cart2219-1-for-adults-and-children-with-relapsed-or-refractory-b-cell-malignancies/ This clinical trial is focused on studying a treatment for certain types of blood cancers, specifically relapsed or refractory B-cell malignancies. These are cancers that have returned or are not responding to treatment. The study involves a new treatment called MB-CART2219.1, which is a type of cell therapy. This therapy is designed to target specific proteins, CD19 and CD22, found on the surface of cancer cells. The treatment is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and feasibility of using MB-CART2219.1 in patients with these types of blood cancers. The study will include both adults and children who have these cancers and have not responded to other treatments. Participants will receive the treatment and be monitored over time to see how their cancer responds and to check for any side effects. The study aims to understand how well the treatment works and how it affects the body.

Throughout the study, researchers will collect information on how the treatment affects the cancer and the immune system. This includes looking at how the cancer cells respond to the treatment and how the immune cells in the body react. The study will also track the overall health and survival of participants over time. This research is important for developing new treatments for blood cancers that are difficult to treat with existing therapies.

]]> Study of CD19-CAR_Lenti, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia or Aggressive B-Cell Lymphomas https://clinicaltrials.eu/trial/study-of-cd19-car_lenti-fludarabine-and-cyclophosphamide-in-children-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-aggressive-b-cell-lymphomas/ Wed, 29 Apr 2026 15:03:15 +0000 https://clinicaltrials.eu/trial/study-of-cd19-car_lenti-fludarabine-and-cyclophosphamide-in-children-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-aggressive-b-cell-lymphomas/ This clinical trial is focused on studying certain types of blood cancers in children and young adults. The diseases being studied are relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and aggressive types of B-cell Non-Hodgkin Lymphoma (B-NHL), which include Diffuse Large B Cell Lymphoma (DLBCL) and Primary Mediastinal B Cell Lymphoma (PML). These are conditions where the cancer has returned after treatment or has not responded to previous treatments.

The study is testing a new treatment called CD19-CAR_Lenti, which involves using the patient’s own immune cells, called T-cells, that are modified in the lab to better recognize and attack cancer cells. This treatment is given through an infusion into the bloodstream. In addition to CD19-CAR_Lenti, the study also uses two other medications, Fludarabine Phosphate and Cyclophosphamide, which are types of chemotherapy drugs that help prepare the body to receive the modified T-cells.

The purpose of the study is to find out how safe and effective the CD19-CAR_Lenti treatment is for these types of cancer. Participants will receive the treatment and be monitored over time to see how their cancer responds. The study will look at how well the treatment works in reducing cancer cells and how long the effects last. Participants will have regular check-ups and tests to track their progress and any side effects they might experience. The study aims to determine the best dose of the treatment and to see if it can help achieve remission, which means the cancer is no longer detectable in the body.

]]> Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-comparing-ponatinib-and-imatinib-with-chemotherapy-for-patients-55-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:02:51 +0000 https://clinicaltrials.eu/trial/study-comparing-ponatinib-and-imatinib-with-chemotherapy-for-patients-55-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer known as Acute Lymphoblastic Leukemia (ALL), specifically in patients who have a genetic feature called the Philadelphia chromosome or BCR-ABL positive. The study is designed for patients aged 55 and older. The purpose of the study is to compare the effects of two different treatments when combined with standard chemotherapy. One treatment involves the drug Ponatinib, also known by its code name AP-24534, and the other involves the drug Imatinib.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ponatinib along with chemotherapy, while the other group will receive Imatinib with chemotherapy. Both medications are taken orally in the form of film-coated tablets. The study will monitor the participants over a period to observe the safety and effectiveness of these treatments. The goal is to see how well each treatment works in reducing the cancer cells in the body and to compare the side effects experienced by participants in each group.

Throughout the study, participants will undergo regular check-ups and tests to track their response to the treatment. The study aims to provide valuable information on which combination of drugs is more effective in treating this specific type of blood cancer. The results could help improve treatment options for patients with Philadelphia chromosome positive Acute Lymphoblastic Leukemia in the future.

]]> Study of CARCIK-CD19 Cells for Patients with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-carcik-cd19-cells-for-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:02:34 +0000 https://clinicaltrials.eu/trial/study-of-carcik-cd19-cells-for-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called B cell precursor Acute Lymphoblastic Leukemia (BCP-ALL). This disease affects both children and adults and is characterized by the presence of cancerous cells in the bone marrow. The treatment being tested in this study is called PTG-CARCIK-CD19, which involves using special cells known as CARCIK-CD19 cells. These cells are designed to target and fight the cancer cells in the body.

The purpose of the study is to confirm how well patients respond to the treatment after receiving the first infusion of CARCIK-CD19 cells and to see if the response lasts longer. Participants in the study will receive one or two infusions of these cells. The study will monitor the patients’ response to the treatment at different points in time, specifically looking at the overall response rate 28 days after the first infusion and the duration of response from day 70 for those who achieve and maintain remission.

Additionally, the study will assess the overall survival of patients, which means the time from receiving the infusion to any potential death. It will also evaluate the safety of administering the CARCIK-CD19 cells, whether they are from a donor (allogeneic), from the patient themselves (autologous), or from cord blood. The study aims to provide valuable information on the effectiveness and safety of this innovative treatment for patients with relapsed or refractory BCP-ALL.

]]> Study of Inotuzumab Ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-inotuzumab-ozogamicin-in-adult-patients-with-b-cell-acute-lymphoblastic-leukemia-and-minimal-residual-disease-before-transplantation/ Wed, 29 Apr 2026 15:02:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-inotuzumab-ozogamicin-in-adult-patients-with-b-cell-acute-lymphoblastic-leukemia-and-minimal-residual-disease-before-transplantation/ This study focuses on adults with B-cell Acute Lymphoblastic Leukemia, a rare type of blood cancer that affects cells that develop into white blood cells. The study specifically looks at patients who have minimal residual disease (small numbers of cancer cells that remain after treatment) before receiving a hematopoietic stem cell transplantation (a procedure that replaces blood-forming cells).

The main treatment being studied is Inotuzumab Ozogamicin (also known as Besponsa), which will be given through an intravenous infusion. Additional medications that may be used in the treatment include Cyclophosphamide, Methotrexate, Prednisone, Ponatinib, Vincristine, and Mercaptopurine. The purpose of the study is to determine how well Inotuzumab Ozogamicin works in eliminating remaining cancer cells in patients.

The treatment period may last up to two years, during which patients will receive the study medication through regular infusions. Throughout the study, doctors will monitor the presence of cancer cells and track how patients respond to the treatment. They will also watch for any side effects that may occur during or after the treatment.

]]> Study of Ziftomenib with Chemotherapy for Children with Relapsed or Refractory Acute Leukemia https://clinicaltrials.eu/trial/study-of-ziftomenib-with-chemotherapy-for-children-with-relapsed-or-refractory-acute-leukemia/ Wed, 29 Apr 2026 15:01:56 +0000 https://clinicaltrials.eu/trial/study-of-ziftomenib-with-chemotherapy-for-children-with-relapsed-or-refractory-acute-leukemia/ This clinical trial is focused on studying treatments for children with certain types of acute leukemia, which is a cancer of the blood and bone marrow. The specific types of leukemia being studied include Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, and Acute Lymphocytic Leukemia. The trial will test a new treatment called Ziftomenib, also known by its code name KO-539, in combination with standard chemotherapy drugs. Chemotherapy drugs used in this study include Cytarabine and Fludarabine phosphate, which are given through injections or infusions. The purpose of the study is to find the best dose of Ziftomenib when used with these chemotherapy drugs.

Participants in the study will receive Ziftomenib in the form of a hard capsule taken by mouth, along with chemotherapy. The study will also include a group receiving a placebo, which is a substance with no active medication. The trial aims to determine the safety and how the body processes Ziftomenib, as well as to observe any side effects. The study will monitor participants over a period of time to assess the effectiveness of the treatment and any potential improvements in their condition.

The trial is designed for children who have experienced a return of their leukemia or whose leukemia has not responded to previous treatments. The study will help researchers understand how well Ziftomenib works in combination with chemotherapy and will provide important information about its safety and potential benefits for treating these types of leukemia in children. The estimated completion date for the study is the end of 2028.

]]> Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy https://clinicaltrials.eu/trial/long-term-safety-study-of-auto4-and-rituximab-in-patients-with-potential-malignancy-treated-with-autologous-car-t-cell-therapy/ Wed, 29 Apr 2026 15:01:40 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-auto4-and-rituximab-in-patients-with-potential-malignancy-treated-with-autologous-car-t-cell-therapy/ This clinical trial focuses on the long-term follow-up of patients who have previously been treated with a special type of therapy called CAR T cell therapy. This therapy involves using a patient’s own T cells, which are a type of immune cell, that have been genetically modified to better fight certain diseases. The diseases being studied in this trial are potential cancers that may develop in patients who have received this therapy. The main goal of the study is to monitor the long-term safety of these treatments.

The study involves two specific treatments: AUTO1 and AUTO4, both of which are types of CAR T cell therapies. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. Another treatment involved in the study is rituximab, known by the brand name MabThera, which is also given as an infusion. Rituximab is a medication that targets specific proteins on the surface of certain cells and is used in various conditions, including some types of cancer.

During the course of the study, participants will be monitored for any serious side effects related to the CAR T cell therapy, the development of new cancers, and other specific health events of interest. The study will also track overall survival rates and the duration of any supportive care needed. Additionally, researchers will look for any remaining genetic material from the therapy in the blood and check for any potential causes of new cancers. This follow-up will continue for up to 15 years after the initial CAR T cell therapy infusion.

]]> Study of ARI-0001 Cells for Children and Adolescents with Resistant or Refractory Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-ari-0001-cells-for-children-and-adolescents-with-resistant-or-refractory-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:01:37 +0000 https://clinicaltrials.eu/trial/study-of-ari-0001-cells-for-children-and-adolescents-with-resistant-or-refractory-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called acute lymphoblastic leukemia (ALL) in children and adolescents aged 0-18 years. The study is specifically for those whose leukemia is resistant or does not respond to standard treatments. The main treatment being tested is called Varnimcabtagene autoleucel, also known by its code name ARI-0001. This treatment involves using a patient’s own immune cells, which are modified in a laboratory to better recognize and attack cancer cells. These modified cells are then infused back into the patient’s body.

In addition to Varnimcabtagene autoleucel, the study involves several other medications that may be used to support the treatment process. These include cytarabine, dexchlorpheniramine maleate, human immunoglobulin G, allopurinol, methylprednisolone, etoposide, fludarabine, tocilizumab, paracetamol, and cyclophosphamide. These medications serve various roles, such as chemotherapy, antihistamines, and other supportive therapies.

The purpose of the study is to evaluate how effective the ARI-0001 cells are in treating patients with this type of leukemia. Participants will receive the treatment and be monitored over a period of time to assess their response. The study will track the complete response rate, which includes remission and recovery of blood cell counts, as well as other outcomes like survival rates and any side effects. The study aims to provide valuable information on the potential benefits and risks of this new treatment approach for children and adolescents with difficult-to-treat acute lymphoblastic leukemia.

]]> Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers https://clinicaltrials.eu/trial/study-of-rapcabtagene-autoleucel-and-ibrutinib-for-adults-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-and-other-blood-cancers/ Wed, 29 Apr 2026 15:01:19 +0000 https://clinicaltrials.eu/trial/study-of-rapcabtagene-autoleucel-and-ibrutinib-for-adults-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-and-other-blood-cancers/ This clinical trial is focused on studying several types of blood cancers, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), and High-Risk Large B-Cell Lymphoma (HR LBCL). The main treatment being tested is called Rapcabtagene Autoleucel, also known by its code name YTB323. This treatment involves using a patient’s own immune cells, which are modified to better fight cancer. The study also involves other medications, such as Ibrutinib, Tocilizumab, Cytarabine, Fludarabine Phosphate, Etoposide, Bendamustine Hydrochloride, and Cyclophosphamide Monohydrate.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

]]> Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-comparing-inotuzumab-ozogamicin-to-drug-combination-for-children-with-high-risk-relapsed-b-cell-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:00:42 +0000 https://clinicaltrials.eu/trial/study-comparing-inotuzumab-ozogamicin-to-drug-combination-for-children-with-high-risk-relapsed-b-cell-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called Acute Lymphoblastic Leukemia (ALL), specifically in children who have experienced a high-risk first relapse. The study is comparing a new treatment using a medication called Inotuzumab Ozogamicin with a standard treatment known as ALLR3. The purpose of the study is to determine if Inotuzumab Ozogamicin is more effective than the standard treatment in helping children with this type of leukemia.

Participants in the study will receive either Inotuzumab Ozogamicin or the standard treatment. Inotuzumab Ozogamicin is given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will last for a period of up to 28 days, during which the effects of the treatment will be closely monitored. Other medications that may be used in the study include Dexamethasone, Pegaspargase, Vincristine Sulfate, and Mitoxantrone Hydrochloride, which are commonly used in treating leukemia.

The study aims to see if the new treatment can help achieve a state where no cancer cells are detectable in the blood, known as minimal residual disease-negative status. This is an important goal in treating leukemia, as it indicates a better response to treatment. The study will also look at other outcomes, such as the time it takes for the disease to progress, the duration of response to treatment, and overall survival rates. Participants will be monitored for any side effects or adverse events during the study period.

]]> Study on the Safety and Effectiveness of Tafasitamab for Children with Relapsed or Refractory Acute B Lineage Leukemia https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tafasitamab-for-children-with-relapsed-or-refractory-acute-b-lineage-leukemia/ Wed, 29 Apr 2026 15:00:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tafasitamab-for-children-with-relapsed-or-refractory-acute-b-lineage-leukemia/ This clinical trial is focused on studying a type of cancer called Acute B Lineage Leukemia in children. This is a form of leukemia, which is a cancer of the blood and bone marrow. The study is specifically for pediatric patients who have either not responded to standard treatments or have experienced a return of the disease after treatment. The treatment being tested in this study is a medication called Tafasitamab, also known by its code name MOR00208. Tafasitamab is a type of protein designed to target and help destroy cancer cells.

The purpose of the study is to evaluate the safety and effectiveness of Tafasitamab in treating children with this type of leukemia. Participants in the study will receive the medication through an intravenous infusion, which means it will be administered directly into a vein. The study will observe participants over a period of time to see how long it takes for the leukemia to return or worsen, and to monitor any side effects or changes in the disease. The study will also look at how the medication affects the overall survival of the participants and whether it can reduce the amount of cancer cells in the body.

Throughout the study, researchers will collect information on how the medication is processed in the body and any potential side effects. The study aims to provide valuable insights into the treatment of Acute B Lineage Leukemia in children, potentially leading to better treatment options in the future. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study on Nivolumab and Tisagenlecleucel for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia After Treatment Loss https://clinicaltrials.eu/trial/study-on-nivolumab-and-tisagenlecleucel-for-children-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia-after-treatment-loss/ Wed, 29 Apr 2026 15:00:31 +0000 https://clinicaltrials.eu/trial/study-on-nivolumab-and-tisagenlecleucel-for-children-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia-after-treatment-loss/ This clinical trial is focused on studying a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) in children, adolescents, and young adults. The study involves two treatments: Nivolumab, also known by its brand name Opdivo, and Tisagenlecleucel, known as Kymriah. Nivolumab is a medication that helps the immune system attack cancer cells, while Tisagenlecleucel is a type of cell therapy that uses modified immune cells to target and destroy cancer cells.

The purpose of the study is to determine the safety and effectiveness of combining these two treatments in patients who have previously been treated with Tisagenlecleucel but have experienced a return of their leukemia. The study will explore different timing options for starting Nivolumab to find the safest and most effective approach. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, researchers will monitor participants for any side effects and assess how well the treatments are working. The study aims to improve understanding of how these treatments can be used together to help patients with relapsed or difficult-to-treat ALL. The trial will take place over several years, with regular follow-ups to track the long-term effects and benefits of the treatment combination.

]]> Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) https://clinicaltrials.eu/trial/study-on-ponatinib-and-chemotherapy-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-ph-all/ Wed, 29 Apr 2026 14:59:20 +0000 https://clinicaltrials.eu/trial/study-on-ponatinib-and-chemotherapy-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-ph-all/ This clinical trial is focused on studying a type of blood cancer called Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). The study aims to evaluate the effectiveness of a medication called Ponatinib, which may be used alone or in combination with other chemotherapy drugs. The chemotherapy drugs involved in this study include Cytarabine, Methylprednisolone, Methotrexate, Vincristine, and Prednisone. These medications are used to help manage the disease by reducing the number of cancer cells in the body.

The purpose of the study is to see how well Ponatinib works in helping patients achieve remission, which means reducing or eliminating signs of cancer. The study will look at patients who have persistent or relapsed disease, as well as those who have not achieved remission after previous treatments. Participants will receive treatment over a period of time, and their response to the medication will be monitored. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, the safety and side effects of the treatments will be closely monitored. The study will also explore how the treatment affects the presence of specific genetic changes in the cancer cells, such as mutations in the BCR-ABL1 gene. The goal is to understand how these treatments can help patients achieve better outcomes and improve their quality of life. The study is expected to continue until 2026, providing valuable information on the management of Ph+ ALL.

]]> Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-obinutuzumab-and-rituximab-with-chemotherapy-for-adults-with-newly-diagnosed-cd20-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:58:36 +0000 https://clinicaltrials.eu/trial/study-on-obinutuzumab-and-rituximab-with-chemotherapy-for-adults-with-newly-diagnosed-cd20-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called acute lymphoblastic leukemia (ALL), specifically in adults who have a newly diagnosed form of this disease that is positive for a marker known as CD20. The study is comparing two treatments: obinutuzumab and rituximab, both of which are given in combination with chemotherapy. These treatments are solutions that are administered through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective these treatments are in helping patients achieve complete remission, which means that signs of cancer are reduced or disappear. The study will monitor patients to see if they reach a state where less than 0.1% of their bone marrow cells show signs of the disease after the initial treatment phase. This is an important measure of success in treating ALL.

Participants in the study will receive one of the two treatments and will be observed over a period of time to assess their response to the treatment. The study will also track the overall health and survival of the participants, as well as any side effects they may experience. The goal is to determine which treatment is more effective and safer for patients with this type of leukemia.

]]> Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-venetoclax-and-blinatumomab-for-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:58:16 +0000 https://clinicaltrials.eu/trial/study-of-venetoclax-and-blinatumomab-for-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL). This condition occurs when the cancer returns or does not respond to treatment. The study is testing a combination of two treatments: Venetoclax and Blinatumomab. Venetoclax, also known by its code names ABT-199 and GDC-0199, is a medication that comes in the form of film-coated tablets and is taken orally. Blinatumomab is a medication given through an intravenous infusion, which means it is administered directly into the bloodstream.

The purpose of this study is to determine how safe and tolerable the combination of Venetoclax and Blinatumomab is for patients, as well as to find the best dose to use. The study will also evaluate how well patients respond to this combination treatment. The trial is divided into two phases. In the first phase, researchers will focus on understanding the safety and appropriate dosage of the treatment. In the second phase, they will assess how effective the treatment is in helping patients with BCP-ALL.

Participants in the study will receive the combination of Venetoclax and Blinatumomab, and some may receive a placebo. The study will continue until the researchers gather enough information to understand the effects of the treatment. This trial aims to provide valuable insights into the potential benefits of combining these two medications for treating BCP-ALL, offering hope for improved outcomes in patients with this challenging condition.

]]> Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-ponatinib-and-imatinib-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:58:04 +0000 https://clinicaltrials.eu/trial/study-on-ponatinib-and-imatinib-for-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called Acute Lymphoblastic Leukemia (ALL), specifically a form that is positive for the Philadelphia Chromosome. The study aims to evaluate the effectiveness of different treatments for this condition. The treatments being tested include a medication called Ponatinib, another medication named Imatinib, and a drug known as Blinatumomab. These medications are used in combination with low-intensity chemotherapy, which is a treatment that uses drugs to kill cancer cells or stop them from growing.

The purpose of the study is to compare the effectiveness of these treatments in patients with this specific type of leukemia. Participants will receive either Ponatinib or Imatinib along with chemotherapy. In some cases, Blinatumomab will be used for patients who respond optimally or suboptimally to the initial treatment. The study will also look at the end of therapy with an indication for stem cell transplantation (SCT) versus the use of these medications and chemotherapy.

The study will take place over several weeks, with different phases of treatment. Participants will receive the medications either orally or through an intravenous infusion, which means the medicine is given directly into a vein. The trial will monitor the overall survival of patients and the rate of complete remission, which means the disappearance of all signs of cancer in response to treatment. The goal is to determine which combination of treatments is most effective for patients with this type of leukemia.

]]> Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-chemotherapy-drug-combination-for-children-with-acute-lymphoblastic-leukemia-and-jak-stat-pathway-activation/ Wed, 29 Apr 2026 14:57:43 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-and-chemotherapy-drug-combination-for-children-with-acute-lymphoblastic-leukemia-and-jak-stat-pathway-activation/ This clinical trial is focused on studying a type of cancer called Acute Lymphoblastic Leukemia (ALL) in children. The study involves a treatment that includes a medication called Ruxolitinib and a specific chemotherapy regimen known as AIEOP-BFM 2017 Poland. The purpose of the study is to explore the effectiveness of this treatment combination in children with ALL who have a specific genetic activation known as the JAK/STAT pathway.

Participants in the study will receive Ruxolitinib along with chemotherapy. The chemotherapy includes several medications such as Ifosfamide, Doxorubicin Hydrochloride, Daunorubicin, Asparaginase, Vindesine Sulfate, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Vincristine Sulfate, Pegaspargase, Mercaptopurine, Etoposide, and Tioguanine. These medications are used to target and kill cancer cells. Some of these drugs are given through an injection into a vein (intravenous), while others are taken by mouth (oral).

The study will follow participants over a period to monitor their response to the treatment. The main goal is to see how many patients achieve a state where no cancer cells are detectable in their blood, known as MRD-negative status. The study will also look at the time it takes for any cancer-related events to occur, such as relapse or resistance to treatment, and will monitor any side effects experienced by the participants. The trial is expected to continue until 2029.

]]> Study on CART 19/22 T Cells and CART45RA-NKG2D Cells for Treating Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults https://clinicaltrials.eu/trial/study-on-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-treating-refractory-relapsed-acute-lymphoblastic-leukemia-in-children-adolescents-and-young-adults/ Wed, 29 Apr 2026 14:57:35 +0000 https://clinicaltrials.eu/trial/study-on-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-treating-refractory-relapsed-acute-lymphoblastic-leukemia-in-children-adolescents-and-young-adults/ This clinical trial is focused on studying a type of blood cancer called acute lymphoblastic leukemia (ALL), which can be difficult to treat when it comes back or does not respond to standard treatments. The study is specifically for children, adolescents, and young adults who have this condition. The trial will explore the use of two different cell therapies: CART 19/22 T cells and CART45RA-NKG2D cells. These treatments involve using special cells that are designed to target and fight the cancer cells in the body. The CART 19/22 T cells are used for a type of ALL that involves certain markers called CD19 and CD22, while the CART45RA-NKG2D cells are used for another type of ALL known as T-ALL.

The purpose of the study is to determine how safe and feasible these treatments are for patients. Participants will receive the treatment through an intravenous infusion, which means the cells are given directly into the bloodstream. The study will monitor the patients to see how their bodies respond to the treatment and to check for any side effects. Some participants may receive a placebo, which is a substance with no active treatment, to help compare the effects of the actual treatment.

Throughout the study, researchers will collect samples from the patients, such as blood and bone marrow, to understand how the treatment is working. They will also look at specific markers in the cancer cells and the patients’ immune responses. The trial aims to provide valuable information on whether these new cell therapies can be a safe and effective option for treating relapsed or refractory acute lymphoblastic leukemia in young patients.

]]> Study on the Safety and Feasibility of CART 19/22 T Cells and CART45RA-NKG2D Cells for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-the-safety-and-feasibility-of-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-children-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:29:38 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-feasibility-of-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-children-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called acute lymphoblastic leukemia (ALL), which can be difficult to treat when it comes back or does not respond to standard treatments. The study is specifically for children, adolescents, and young adults who have this condition. The trial will explore the use of two different cell therapies: CART45RA-NKG2D cells and CART 19/22 T cells. These are special treatments that involve using modified cells to help the body fight the cancer.

The purpose of the study is to assess the safety and feasibility of these treatments. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will be conducted in different groups, with each group receiving one of the two treatments. The trial will monitor how well the treatments work and how long the modified cells stay in the body. It will also look at the body’s response to the treatment, including any changes in the blood and other samples.

The trial aims to provide new insights into treating acute lymphoblastic leukemia in young patients who have limited options. By participating in this study, researchers hope to find more effective ways to manage this challenging condition and improve outcomes for those affected. The study is expected to continue until the end of 2028, with recruitment starting in mid-2024.

]]> Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia https://clinicaltrials.eu/trial/infusion-study-of-ari-0001-cells-for-patients-with-resistant-or-refractory-cd19-acute-lymphoid-leukemia/ Wed, 29 Apr 2026 14:29:31 +0000 https://clinicaltrials.eu/trial/infusion-study-of-ari-0001-cells-for-patients-with-resistant-or-refractory-cd19-acute-lymphoid-leukemia/ This clinical trial is focused on studying a type of blood cancer called acute lymphoid leukemia, specifically in patients whose disease is resistant or does not respond to standard treatments. The main treatment being tested in this study is called Varnimcabtagene autoleucel, also known by its code name ARI-0001. This treatment involves using a patient’s own immune cells, which are collected, modified in a laboratory to better fight cancer, and then infused back into the patient. The study aims to evaluate how effective this treatment is in helping patients with this type of leukemia.

In addition to ARI-0001, other medications may be used during the study, including Bendamustine, Fludarabine, Cyclophosphamide, Tocilizumab, Dexchlorpheniramine, Paracetamol, and Allopurinol. These medications serve various purposes, such as chemotherapy, managing side effects, or supporting the patient’s overall health during the trial. The study will also include a placebo group to compare the effects of the treatment.

Participants in the study will receive the ARI-0001 treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will monitor patients over a period to assess the response to the treatment, the duration of the response, and any side effects that may occur. The goal is to determine if ARI-0001 can effectively treat acute lymphoid leukemia and improve patient outcomes. The study will also track the survival of the modified cells in the body and any potential adverse effects related to the treatment.

]]> Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination https://clinicaltrials.eu/trial/study-on-improving-treatment-for-children-and-adolescents-with-acute-lymphoblastic-leukemia-using-bortezomib-blinatumomab-and-a-drug-combination/ Wed, 29 Apr 2026 14:27:39 +0000 https://clinicaltrials.eu/trial/study-on-improving-treatment-for-children-and-adolescents-with-acute-lymphoblastic-leukemia-using-bortezomib-blinatumomab-and-a-drug-combination/ This clinical trial is focused on studying treatments for acute lymphoblastic leukemia in children and adolescents. The study aims to explore the effectiveness of different treatment strategies to improve outcomes for patients with this type of cancer. The trial involves several medications, including Oncaspar (pegaspargase), BLINCYTO (blinatumomab), Erwinase (crisantaspase), and other chemotherapy drugs such as prednisolone, etoposide, bortezomib, methotrexate, cyclophosphamide, vincristine, ifosfamide, cytarabine, doxorubicin, fludarabine, mercaptopurine, and tioguanine. Some patients will receive a placebo as part of the study.

The purpose of the study is to determine if adding certain medications or changing the treatment schedule can improve the chances of staying cancer-free for longer periods. The study will compare different groups of patients who receive various combinations of these treatments. For example, one group will receive additional therapy with the drug bortezomib during a phase called consolidation, while another group will receive blinatumomab as part of their treatment plan. The study will also look at whether extending the treatment phase and increasing doses of certain drugs like cyclophosphamide, cytarabine, and 6-mercaptopurine can improve outcomes.

Participants in the study will follow a treatment plan that includes receiving medications through injections or infusions, and some drugs may be taken orally. The study will monitor the participants over time to see how well the treatments work and to check for any side effects. The goal is to find the best treatment approach for children and adolescents with acute lymphoblastic leukemia to improve their chances of recovery and long-term health.

]]> Study on the Safety and Effectiveness of AUTO1 for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Using a Drug Combination https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-auto1-for-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-using-a-drug-combination/ Wed, 29 Apr 2026 14:27:36 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-auto1-for-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-using-a-drug-combination/ This clinical trial is focused on studying a type of blood cancer called relapsed or refractory B cell acute lymphoblastic leukemia. This condition occurs when the cancer returns or does not respond to treatment. The study is testing a new treatment called AUTO1, which is a special kind of therapy that uses the patient’s own immune cells, known as T cells. These T cells are modified in a laboratory to better recognize and attack cancer cells. The purpose of the study is to evaluate the safety and effectiveness of this treatment.

Participants in the study will receive the AUTO1 treatment through an infusion, which means it is given directly into the bloodstream. The study will monitor how well the treatment works and any side effects that may occur. The trial will also compare the results with those of other treatments, such as Paracetamol, Fludarabine, and Cyclophosphamide, which are used for different purposes in cancer treatment. Some participants may receive a placebo, which is a substance with no active medication, to help understand the effects of the new treatment.

The study will take place over several months, and participants will have regular check-ups to assess their health and the progress of the treatment. The goal is to find out if AUTO1 can help patients with this type of leukemia and to ensure it is safe for use. This research is important for developing new and effective treatments for people with this challenging condition.

]]> Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-ponatinib-and-chemotherapy-for-adults-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:27:16 +0000 https://clinicaltrials.eu/trial/study-of-ponatinib-and-chemotherapy-for-adults-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia/ This clinical trial is focused on treating a specific type of leukemia called Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL), particularly a subtype known as BCR/ABL1-like ALL. The study involves using a medication called Ponatinib, which is a type of drug known as a tyrosine kinase inhibitor, in combination with various chemotherapy drugs. The chemotherapy drugs used in this study include Dexamethasone Disodium Phosphate, Vincristine Sulfate, Mercaptopurine, Filgrastim, Idarubicin Hydrochloride, Lenograstim, Prednisone, Cyclophosphamide, Cytarabine, Folinic Acid, Methotrexate, and Methylprednisolone Sodium Succinate. Some patients may receive a placebo as part of the study.

The purpose of the study is to see how well this combination of treatments works in helping patients achieve remission, which means the disease is no longer detectable, even at a very detailed level. The study will follow patients over a period of time to monitor their response to the treatment. Participants will receive the treatment in cycles, and their health will be closely monitored throughout the study to assess the effectiveness and safety of the treatment.

During the study, patients will receive the treatment through different methods, such as oral tablets or injections, depending on the specific medication. The study aims to improve the percentage of patients who achieve remission and to understand the long-term outcomes of using Ponatinib with chemotherapy. The study will also track any side effects or adverse events that may occur during the treatment. The overall goal is to find a more effective treatment approach for patients with this type of leukemia.

]]> Study on the Safety and Effects of AUTO1, Cyclophosphamide, and Fludarabine Phosphate in Children with Relapsed or Refractory B-cell Leukemia and Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-auto1-cyclophosphamide-and-fludarabine-phosphate-in-children-with-relapsed-or-refractory-b-cell-leukemia-and-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:26:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-auto1-cyclophosphamide-and-fludarabine-phosphate-in-children-with-relapsed-or-refractory-b-cell-leukemia-and-non-hodgkin-lymphoma/ This clinical trial is focused on studying two types of blood cancers: B-cell Acute Lymphoblastic Leukemia (B-ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B-NHL). These are serious conditions where certain white blood cells grow uncontrollably. The study is testing a new treatment called AUTO1, which involves using a patient’s own immune cells that are specially modified to target and fight the cancer cells. This treatment is given through an infusion, which means it is delivered directly into the bloodstream.

The purpose of the study is to evaluate the safety and initial effectiveness of AUTO1 in children who have these types of cancers that have either returned after treatment or have not responded to previous treatments. Participants in the study will receive the AUTO1 treatment and will be monitored closely by healthcare professionals. The study will look at how well the treatment is tolerated and any side effects that may occur. It will also assess how the cancer responds to the treatment over time.

In addition to AUTO1, the study involves two other medications, Cyclophosphamide and Fludara (fludarabine phosphate), which are used to prepare the body for the AUTO1 treatment. These medications are also given through an infusion. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment. The study is expected to continue until 2027, with participants being followed up regularly to gather information on the treatment’s long-term effects and benefits.

]]> Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer https://clinicaltrials.eu/trial/study-on-trametinib-dexamethasone-cyclophosphamide-and-cytarabine-for-children-with-relapsed-or-refractory-blood-cancer/ Wed, 29 Apr 2026 14:26:45 +0000 https://clinicaltrials.eu/trial/study-on-trametinib-dexamethasone-cyclophosphamide-and-cytarabine-for-children-with-relapsed-or-refractory-blood-cancer/ This clinical trial is focused on studying certain types of blood cancers in children, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, which can be either in relapse or resistant to treatment. The study aims to explore the effects of a combination of medications, including Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine. These medications are being tested to see how safe they are and how well they work in treating these cancers.

The trial is divided into two phases. In the first phase, the focus is on determining the safest dose of the medications that can be given to patients. The second phase aims to evaluate how effective these medications are in treating patients with specific genetic changes in their cancer cells. The study involves taking these medications in different forms, such as tablets or injections, over a period of time. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, the health and progress of the participants will be closely monitored. This includes regular check-ups and tests to assess how the body is responding to the treatment. The goal is to gather information that could lead to better treatment options for children with these challenging types of blood cancer. The study is expected to continue until 2030, with the hope of providing valuable insights into the treatment of these diseases.

]]> Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-methotrexate-and-dexamethasone-for-infants-under-one-year-with-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:24:52 +0000 https://clinicaltrials.eu/trial/study-on-methotrexate-and-dexamethasone-for-infants-under-one-year-with-acute-lymphoblastic-leukemia/ This clinical trial is focused on treating infants under one year old who have been diagnosed with a specific type of blood cancer called acute lymphoblastic leukemia (ALL) or a similar condition known as mixed phenotype acute leukemia (MPAL). The study aims to improve the outcomes for these young patients by using a treatment protocol called Interfant-21. This protocol includes a combination of medications that are commonly used in cancer treatment. These medications include methotrexate, dexamethasone, tioguanine, daunorubicin, vincristine sulfate, mitoxantrone, asparaginase, cyclophosphamide monohydrate, etoposide, mercaptopurine, prednisone, and blinatumomab. Some of these medications are given as injections, while others are taken orally as tablets or suspensions.

The purpose of the study is to see if this new treatment approach can help improve the chances of survival without the cancer coming back. The study will follow the infants through different phases of treatment, which may include receiving some of these medications in a hospital setting. The treatment plan is designed to be as effective as possible while minimizing side effects. The study will also compare the results to previous treatment protocols to see if there is an improvement in outcomes.

Throughout the study, the infants will be closely monitored by healthcare professionals to ensure their safety and to track their progress. The study will collect information on how well the treatment works, any side effects experienced, and the overall health of the infants. This information will help doctors understand more about how to treat this type of leukemia in very young children and may lead to better treatment options in the future.

]]> Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents https://clinicaltrials.eu/trial/study-on-pegaspargase-for-treating-acute-lymphoblastic-leukemia-in-children-and-adolescents/ Wed, 29 Apr 2026 14:23:13 +0000 https://clinicaltrials.eu/trial/study-on-pegaspargase-for-treating-acute-lymphoblastic-leukemia-in-children-and-adolescents/ This clinical trial is focused on studying acute lymphoblastic leukemia (ALL), a type of cancer that affects the blood and bone marrow, in children and adolescents. The treatment being tested in this study is called pegaspargase, which is a medication used to treat ALL. Pegaspargase is given as an injection and works by breaking down a substance in the body that cancer cells need to grow.

The purpose of the study is to evaluate how effective and safe different schedules of pegaspargase are for patients aged 12 months to less than 18 years who have been newly diagnosed with standard or medium-risk ALL. The study will also look at the effects of a more intense treatment schedule for those with high or very high-risk ALL. Participants will receive pegaspargase as part of their treatment plan, and the study will monitor how well the medication works and any side effects that may occur.

Throughout the study, researchers will assess the activity of pegaspargase in the body and monitor for any severe side effects, such as issues with the pancreas or allergic reactions. The study will also explore the occurrence of rare subtypes of ALL and their impact on treatment outcomes. The trial aims to provide valuable information on the best ways to use pegaspargase in treating ALL in young patients.

]]> Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-tioguanine-and-drug-combination-for-patients-aged-0-45-with-newly-diagnosed-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:23:05 +0000 https://clinicaltrials.eu/trial/study-on-tioguanine-and-drug-combination-for-patients-aged-0-45-with-newly-diagnosed-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying treatments for Acute Lymphoblastic Leukemia (ALL), a type of cancer that affects the blood and bone marrow. The study aims to improve the survival and quality of life for children and young adults diagnosed with this disease. Participants in the trial will receive various treatments, including medications like Tioguanine, Hydrocortisone Sodium Succinate, Mercaptopurine, Blinatumomab, Vincristine Sulfate, Doxorubicin, Dexamethasone, Methotrexate, Imatinib, Inotuzumab Ozogamicin, Methylprednisolone Sodium Succinate, Prednisolone Sodium Succinate, and Cytarabine. Some participants may receive a placebo as part of the study.

The purpose of the study is to test these treatments in a structured way to see how well they work and to gather information about their effects. The study will involve different phases where participants will receive these treatments over a period of time. The treatments will be given in various forms, such as oral suspensions, tablets, or injections, depending on the specific medication. The study will also explore the potential benefits of new types of treatments, such as immunotherapy, for certain groups of patients.

Throughout the study, participants will be monitored to assess the effectiveness of the treatments and to identify any side effects. The study will collect data on survival rates, the occurrence of any relapses, and the overall quality of life of the participants. This information will help researchers understand how these treatments can be used to improve outcomes for people with Acute Lymphoblastic Leukemia.

]]> Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-imatinib-and-chemotherapy-combination-for-children-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:22:41 +0000 https://clinicaltrials.eu/trial/study-on-imatinib-and-chemotherapy-combination-for-children-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study is testing a medication called imatinib, which is used in combination with different chemotherapy treatments. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. The purpose of this study is to compare how well patients with Ph+ ALL respond to imatinib when it is combined with two different chemotherapy treatment plans.

Participants in the study will receive imatinib along with one of two chemotherapy regimens. These regimens include various medications such as tioguanine, imatinib, doxorubicin hydrochloride, pegaspargase, cytarabine, dexamethasone, prednisone, mercaptopurine, crisantaspase, daunorubicin hydrochloride, ifosfamide, methotrexate, cyclophosphamide, etoposide, vincristine sulfate, and hydrocortisone sodium succinate. Some of these medications are given as tablets, while others are administered through injections or infusions. The study will monitor the participants over a period to see how well the treatment works in preventing the cancer from coming back or worsening.

The trial aims to improve the understanding of how effective imatinib is when used with different chemotherapy combinations in treating Ph+ ALL. Participants will be closely monitored throughout the study to ensure their safety and to gather information on the effectiveness of the treatment. The study will help determine the best treatment approach for patients with this specific type of leukemia.

]]> Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma https://clinicaltrials.eu/trial/study-on-blinatumomab-ponatinib-and-isatuximab-for-adults-aged-18-65-with-newly-diagnosed-acute-lymphoblastic-leukemia-or-t-cell-lymphoblastic-lymphoma/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-on-blinatumomab-ponatinib-and-isatuximab-for-adults-aged-18-65-with-newly-diagnosed-acute-lymphoblastic-leukemia-or-t-cell-lymphoblastic-lymphoma/ This clinical trial is focused on studying treatments for a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) and a related condition known as T-cell Lymphoblastic Lymphoma (T-LL). The study involves several medications, including blinatumomab, isatuximab, and ponatinib. Blinatumomab, also known by its code names MT-103 and MEDI-538, is a type of protein that helps the immune system target cancer cells. Isatuximab, sometimes referred to as SAR650984, is another protein that targets specific markers on cancer cells. Ponatinib, also known as AP-24534, is a chemical compound that blocks certain proteins involved in cancer cell growth.

The purpose of this study is to explore how these new treatments can improve outcomes for adults with newly diagnosed ALL or T-LL. Participants will be divided into different groups to receive these treatments, sometimes in combination with a procedure called Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), which involves replacing diseased bone marrow with healthy cells from a donor. The study will follow participants over a period to observe the effects of these treatments on their health and cancer progression.

Throughout the study, participants will receive either the study medications or a placebo, and their health will be monitored regularly. The study aims to determine if these new treatments can help improve survival rates and reduce the risk of cancer returning. Participants will be closely observed for any side effects and overall quality of life during the treatment period. The study is expected to continue for several years to gather comprehensive data on the effectiveness and safety of these treatments.

]]> Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation https://clinicaltrials.eu/trial/study-of-dasatinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-mapk-src-pathway-mutation/ Wed, 29 Apr 2026 14:22:35 +0000 https://clinicaltrials.eu/trial/study-of-dasatinib-and-venetoclax-for-children-with-relapsed-or-refractory-leukemia-or-lymphoma-with-mapk-src-pathway-mutation/ This clinical trial is focused on studying certain types of blood cancers in children, specifically Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. These conditions are being examined when they have returned after treatment or have not responded to treatment. The study involves two medications: Venetoclax, also known by its code name ABT-199, and Dasatinib. Venetoclax is available as an oral suspension and film-coated tablets, while Dasatinib is available as film-coated tablets and powder for oral suspension. Both medications are designed to target cancer cells and are classified as anti-neoplastic agents, which means they work to stop the growth of cancer cells.

The purpose of this study is to explore the safety and effectiveness of these medications in children with specific genetic changes in their cancer cells. These changes are related to the MAPK/SRC signaling pathway, which is a series of interactions between proteins in a cell that can lead to cancer growth. The study is divided into two phases. The first phase aims to determine the safest dose of the medications, while the second phase evaluates how well the medications work in treating the cancer. Participants will receive either Venetoclax or Dasatinib, or a combination of both, and their health will be monitored closely throughout the study.

During the trial, participants will take the medications orally, either as a liquid or a tablet, depending on the formulation. The study will track various outcomes, such as the overall response to the treatment and the time it takes for the cancer to return, if it does. The trial will also assess the quality of life of participants using a specific questionnaire designed for children with cancer. The study is expected to continue until 2031, with recruitment starting in 2024.

]]>